

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement dated 31 May 2019 (the “**Announcement**”) of Consun Pharmaceutical Group Limited (the “**Company**”) of the major transaction in relation to the cooperative development of the site located at Yulin City, Guangxi Province, the PRC. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the circular (the “**Circular**”) containing, among other things, further details of the Disposals will be despatched to the Shareholders on or before 24 June 2019.

As additional time is required by the Company to finalise certain information in the Circular, including the property valuation report to be included in the Circular, the date of despatch of the Circular will be postponed to on or before 23 August 2019.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 24 June 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.